®, the first FDA-approved digital medicine.
Bill currently serves as Chairman of the Board of Directors of OPDC and is also the Chairman of the Board of the Sozosei Foundation, a newly established Otsuka charitable organization focused on decriminalization of mental illness. He serves on the boards of Excision BioTherapeutics, Saama and Annexon Biosciences and is Trustee of the non-profit Internet2. He is Board Chair Emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts.
“Bill is an eminent figure in the biopharmaceutical community with a proven track record of advancing therapies through clinical development, regulatory approval and commercialization. His appointment demonstrates our ambition to establish Decibel at the forefront of innovation in treatments to restore and improve hearing and balance,” said Laurence Reid, Ph.D., Chief Executive Officer. “Bill is passionate about delivering life-changing therapies in areas of unmet medical
Hearing loss biotech Decibel makes a lackluster public debut
The Boston company, which is working to develop gene therapies, raised $127 million in an IPO, but its stock price closed up just three cents on Friday.
By Jonathan Saltzman Globe Staff,Updated February 12, 2021, 9:51 a.m.
Email to a Friend
Laurence Reid is chief executive of Decibel Therapeutics in Boston.Decibel Therapeutics
After raising $127 million in an initial public offering on Friday, Boston biotech Decibel Therapeutics had a lackluster opening day of trading, with its stock price closing virtually flat.
Decibel, which is developing gene therapies for hearing and balance disorders, had originally filed to sell 5.9 million shares on the Nasdaq exchange. But it ended up offering 7.1 million shares at $18, the high end of the expected range of $16 to $18. It closed Friday at $18.03, an increase of just three cents. The company is listed under the symbol DBTX.